AGEN · Agenus Inc
$9.93
+0.04 (+0.40%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the timing and completion of these transactions are not entirely within our control, in accordance with applicable accounting standards, substantial doubt exists about our ability to continue as a going concern for at least one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 7, 2026
Market Cap
$427.47M
Shares
45.02M
Volume · Sep 30
1.37M
Avg daily vol (3M)
4.21M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.93
Open$9.92
Day$9.62–10.31
52W close$2.77–9.93
Avg vol 30d1.1M
Short int6.8M · 15.1% float · 7.7d
Short vol60%
Last earningsAug 6, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 5 wks
filed Aug 7, 2026
call held Aug 27, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$132.69M
Trailing 12 months
Net income (TTM)
$91.94M
Trailing 12 months
Revenue growth YoY
+34.4%
Year over year
Operating margin
27.3%
Trailing 12 months
P / E (TTM)
3.3
Trailing earnings · reciprocal yield 30.7%
FCF yield
-23.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+47.0%
Year over year · more shares
Price change (1Y)
+148.5%
Trailing year
Short interest
15.1%
Latest settlement · 7.7 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+118%
above
Price vs 50-day avg
+30%
above
RSI (14)
74
overbought
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+24%
trailing
6-month return
+123%
trailing
YTD return
+216%
this year
Relative strength
+111%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.11% of float · ▲ +1.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+90%
Y/Y
EPS growth
+100%
Y/Y
Free cash flow
$-77.2M
Valuation
P/E 4.7
below peers
Balance sheet
$41.7M
net debt
Quant / Vol
risk profile
Volatility
118%
annualized · 1-yr
Max drawdown
−41%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Mar 14, 2024
Cash proceeds from monetizing non-strategic assets, royalty mone
· not stated
$100M – $200M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+118%
Bullish
Price vs 50-day avg
+30%
Bullish
RSI (14)
74
Bearish
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $5 — 50d above 200d
Institutional flow
Accumulating
+19% holders QoQ · +32 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
15.11% of float · ▲ +1.7% MoM · 7.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $10 · 100%
Range high $10
vs 200-day avg +118%
vs 50-day avg +30%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AGEN
this stock
Agenus Inc
|
$427.47M | +216.2% | +89.9% | 4.7 | 15.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AGEN | +18.2% | +24.3% | +123.2% | +30.5% | +216.2% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | +18.9% | +24.2% | +111.0% | +31.1% | +204.4% |